Tesshi Yamada

Prof. Tesshi Yamada

Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
KHKazufumi Honda
Kazufumi Honda
TYTesshi Yamada
Tesshi Yamada
YHYasuharu Hayashida
Yasuharu Hayashida
MIMasashi Idogawa
Masashi Idogawa
SSSatoshi Sato
Satoshi Sato
SHSetsuo Hirohashi
Setsuo Hirohashi

26 August 2016 in Nature Communications
Verified
Journal Article
Open access
MMMari Masuda
Mari Masuda
YUYuko Uno
Yuko Uno
NONaomi Ohbayashi
Naomi Ohbayashi
HOHirokazu Ohata
Hirokazu Ohata
AMAyako Mimata
Ayako Mimata
TYTesshi Yamada
Tesshi Yamada
Canonical Wnt/β-catenin signalling is essential for maintaining intestinal stem cells, and its constitutive activation has been implicated in colorectal carcinogenesis. We and others have previously identified Traf2- and Nck-interacting kinase (TNIK) as an essential regulatory component of the T-cell factor-4 and β-catenin transcriptional complex. Consistent with this, Tnik-deficient mice are resistant to azoxymethane-induced colon tumorigenesis, and Tnik−/−/Apcmin/+ mutant mice develop significantly fewer intestinal tumours. Here we report the first orally available small-molecule TNIK inhibitor, NCB-0846, having anti-Wnt activity. X-ray co-crystal structure analysis reveals that NCB-0846 binds to TNIK in an inactive conformation, and this binding mode seems to be essential for Wnt inhibition. NCB-0846 suppresses Wnt-driven intestinal tumorigenesis in Apcmin/+ mice and the sphere- and tumour-forming activities of colorectal cancer cells. TNIK is required for the tumour-initiating function of colorectal cancer stem cells. Its inhibition is a promising therapeutic approach.

1 April 2005 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NNNobuhiro Nitori
Nobuhiro Nitori
YIYoshinori Ino
Yoshinori Ino
YNYukihiro Nakanishi
Yukihiro Nakanishi
TYTesshi Yamada
Tesshi Yamada
KHKazufumi Honda
Kazufumi Honda
SHSetsuo Hirohashi
Setsuo Hirohashi
Tissue factor (TF) is a transmembrane glycoprotein that plays roles in the blood coagulation and intracellular signaling pathways, and has also been suggested to modulate the biological behavior of cancer cells. In order to examine the clinicopathologic significance of TF expression in pancreatic ductal adenocarcinoma, TF expression was determined by immunohistochemistry using a newly raised anti-TF monoclonal antibody in 113 patients who had undergone surgical resection of pancreatic ductal adenocarcinoma. According to the incidence of tumor cell immunopositivity, patients were divided into “negative TF” (0%), “weak TF” (<25%), or “high TF” (25% or more) groups, which accounted for 11.6% (n = 13), 44.2% (n = 50), and 44.2% (n = 50) of the total, respectively. Increased TF expression was correlated with the extent of the primary tumor (P = 0.0043), lymph node metastasis (P = 0.0043), lymphatic distant metastasis (P = 0.0039), advanced tumor-node-metastasis stage (P = 0.0002), and high tumor grade (P = 0.0164). Multivariate analysis using the Cox proportional hazards model showed that high TF expression was an independent negative predictor for survival (hazard ratio, 2.014; P = 0.0076). Moreover, patients with TF-negative tumors had a significantly better prognosis even if lymph node metastasis was present (P < 0.0001). We also showed that TF knockdown by RNA interference suppressed the invasiveness of a pancreatic adenocarcinoma cell line in vitro. These results indicate that TF expression may contribute to the aggressiveness of pancreatic ductal adenocarcinoma by stimulating tumor invasiveness, and that evaluation of the primary tumor for TF expression may identify patients with a poor prognosis.

14 June 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
MSMiki Shitashige
Miki Shitashige
RSReiko Satow
Reiko Satow
TJTakafumi Jigami
Takafumi Jigami
KAKazunori Aoki
Kazunori Aoki
KHKazufumi Honda
Kazufumi Honda
TYTesshi Yamada
Tesshi Yamada
T-cell factor-4 (TCF4) is a transcription factor essential for maintaining the undifferentiated status and self-renewal of intestinal epithelial cells. It has therefore been considered that constitutive activation of TCF4 by aberrant Wnt signaling is a major force driving colorectal carcinogenesis. We previously identified Traf2- and Nck-interacting kinase (TNIK) as one of the proteins that interact with TCF4 in colorectal cancer cells, but its functional significance has not been elucidated. Here, we report that TNIK is an activating kinase for TCF4 and essential for colorectal cancer growth. TNIK, but not its catalytically inactive mutant, phosphorylated the conserved serine 154 residue of TCF4. Small interfering RNA targeting TNIK inhibited the proliferation of colorectal cancer cells and the growth of tumors produced by injecting colorectal cancer cells s.c. into immunodeficient mice. The growth inhibition was abolished by restoring the catalytic domain of TNIK, thus confirming that its enzyme activity is essential for the maintenance of colorectal cancer growth. Several ATP-competing kinase inhibitors have been applied to cancer treatment and have shown significant activity. Our findings suggest TNIK as a feasible target for pharmacologic intervention to ablate aberrant Wnt signaling in colorectal cancer. Cancer Res; 70(12); 5024–33. ©2010 AACR.

1 May 2015 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
AMAkihiko Miyanaga
Akihiko Miyanaga
MMMari Masuda
Mari Masuda
KTKoji Tsuta
Koji Tsuta
KKKumiko Kawasaki
Kumiko Kawasaki
YNYuka Nakamura
Yuka Nakamura
TYTesshi Yamada
Tesshi Yamada

1 October 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
YHYasuharu Hayashida
Yasuharu Hayashida
KHKazufumi Honda
Kazufumi Honda
MIMasashi Idogawa
Masashi Idogawa
YIYoshinori Ino
Yoshinori Ino
MOMasaya Ono
Masaya Ono
TYTesshi Yamada
Tesshi Yamada
The E-cadherin/catenin system acts as an invasion suppressor of epithelial malignancies. This invasion suppressive activity seems be mediated not only by the cell adhesive activity of E-cadherin but by other undetermined signaling pathways elicited by β-catenin. In fact, cancer cells that have infiltrated the stroma reduce the expression of E-cadherin and accumulate β-catenin. We attempted to identify the alternative partner proteins that make complexes with β-catenin in the absence of E-cadherin. An ∼100-kDa protein was constantly coimmunoprecipitated with β-catenin from SW480 colorectal cancer cells, which lack the expression of E-cadherin, and was identified as actinin-4 by mass spectrometry. Transfection of E-cadherin cDNA suppressed the association between β-catenin and actinin-4. Inhibition of E-cadherin by RNA interference transferred the β-catenin and actinin-4 proteins into the membrane protrusions of DLD-1 cells. Immunofluorescence histochemistry of clinical colorectal cancer specimens showed that the β-catenin and actinin-4 proteins were colocalized in colorectal cancer cells infiltrating the stroma. We reported previously that overexpression of actinin-4 induces cell motility and specifically promotes lymph node metastasis by colorectal cancer. The association between β-catenin and actinin-4 and its regulation by E-cadherin may represent a novel molecular link connecting cell adhesion and motility. Shutting down the signals mediating this association may be worth considering as a therapeutic approach to cancer invasion and metastasis.